J. G. van der Bom

TL;DR: In this paper, the authors studied the mortality, causes of death, and life expectancy of hemophilia patients between 1992 and 2001, compared with those of previous cohorts, together spanning the periods before, during, and after the use of potentially contaminated clotting products.

TL;DR: It is suggested that, compared with a primarily on‐demand treatment strategy, a primarily prophylactic treatment strategy leads to better outcome at equal treatment costs in young adults with severe haemophilia.

TL;DR: This study investigated the optimal analysing strategy for bleeding data by using the association of residual clotting factor level and number of joint bleeds in moderate and mild patients treated on demand as example, and found Multivariate regression analysis using negative binomial distribution provided the optimum data analytical strategy.

TL;DR: High‐dose prophylaxis significantly increases treatment costs and reduces joint bleeds over a period of 3 years, but only slightly reduces arthropathy after 17’years of follow‐up, suggesting that, compared with intermediate‐doseProphylactic regimens, high‐dose Prophylactive regimens significantly increases Treatment costs and joint bleeding over aperiod of 3 years, butonly slightly reducesArthropathy.

TL;DR: These findings show that intensive treatment periods are associated with an increased risk of inhibitor development in previously untreated patients with severe hemophilia A, and the notion that age at first exposure is associated with the risk of developing inhibitors is not supported.